The Experts below are selected from a list of 67056 Experts worldwide ranked by ideXlab platform
Jessica Boklan - One of the best experts on this subject based on the ideXlab platform.
-
Little patients, losing patience: pediatric Cancer Drug Development.
Molecular cancer therapeutics, 2006Co-Authors: Jessica BoklanAbstract:The December 2004 Food and Drug Administration (FDA) approval of clofarabine (Clolar, Genzyme) for refractory pediatric acute lymphoblastic leukemia was a milestone in the history of pediatric Cancer Drug Development. A rare occurrence, it represented approval of a new Cancer Drug for a pediatric
Daniel P. Silver - One of the best experts on this subject based on the ideXlab platform.
-
synthetic lethality a new direction in Cancer Drug Development
The New England Journal of Medicine, 2009Co-Authors: Dirk J Iglehart, Daniel P. SilverAbstract:In this issue of the Journal, Fong et al. report the results of a phase 1 trial of a new Cancer therapy involving 60 patients (ClinicalTrials.gov number, NCT00516373).1 Readers may be surprised by the editors' decision to publish a small early-stage trial, but this trial not only reports important results — it also points to a new direction in the Development of antiCancer Drugs. Modern Cancer-Drug discovery focuses on finding new therapies with few side effects by leveraging advances in the understanding of Cancer biology, but barriers to success are substantial. The story behind the report by Fong et al. . . .
-
Synthetic Lethality ― A New Direction in Cancer-Drug Development
The New England journal of medicine, 2009Co-Authors: J. Dirk Iglehart, Daniel P. SilverAbstract:In this issue of the Journal, Fong et al. report the results of a phase 1 trial of a new Cancer therapy involving 60 patients (ClinicalTrials.gov number, NCT00516373).1 Readers may be surprised by the editors' decision to publish a small early-stage trial, but this trial not only reports important results — it also points to a new direction in the Development of antiCancer Drugs. Modern Cancer-Drug discovery focuses on finding new therapies with few side effects by leveraging advances in the understanding of Cancer biology, but barriers to success are substantial. The story behind the report by Fong et al. . . .
P Bremner - One of the best experts on this subject based on the ideXlab platform.
-
Ethnobotany and ethnopharmacy--their role for anti-Cancer Drug Development.
Curr Drug Targets, 2006Co-Authors: P BremnerAbstract:Local and traditional knowledge has been the starting point for many successful Drug Development projects over the last decades. Here we discuss some examples of anti-Cancer Drugs which have had enormous impact as anti-Cancer agents (camptothecan, taxol and derivatives) and a few examples of Drugs currently under various stages of preclinical Development. Ethnobotanists investigate the relationship between humans and plants in all its complexity, and such research is generally based on a detailed observation and study of the use a society makes of plants. The requirements of modern research on natural products as, for example, outlined in the Convention on Biological Diversity (Rio Convention) and the overall approach in ethnobotanical research are also discussed. Selected phytochemical-pharmacological studies based on traditional plant use are used to highlight the potential of ethnobotany driven anti-Cancer research. The link between traditionally used plants and targets of the NF-kappaB pathway is discussed using on an EU-funded, multidisciplinary project as an example. Lastly the potential of chemopreventive agents derived from traditional food plants is briefly addressed.
Peter J. Houghton - One of the best experts on this subject based on the ideXlab platform.
-
Challenges and Opportunities for Childhood Cancer Drug Development
Pharmacological reviews, 2019Co-Authors: Peter J. Houghton, Raushan T. KurmashevaAbstract:Cancer in children is rare with approximately 15,700 new cases diagnosed in the United States annually. Through use of multimodality therapy (surgery, radiation therapy, and aggressive chemotherapy), 70% of patients will be "cured" of their disease, and 5-year event-free survival exceeds 80%. However, for patients surviving their malignancy, therapy-related long-term adverse effects are severe, with an estimated 50% having chronic life-threatening toxicities related to therapy in their fourth or fifth decade of life. While overall intensive therapy with cytotoxic agents continues to reduce Cancer-related mortality, new understanding of the molecular etiology of many childhood Cancers offers an opportunity to redirect efforts to develop effective, less genotoxic therapeutic options, including agents that target oncogenic drivers directly, and the potential for use of agents that target the tumor microenvironment and immune-directed therapies. However, for many high-risk Cancers, significant challenges remain.
-
integrating pharmacology and in vivo Cancer models in preclinical and clinical Drug Development
European Journal of Cancer, 2004Co-Authors: J K Peterson, Peter J. HoughtonAbstract:Historically, Cancer Drug Development has been a roller coaster. Numerous agents have shown exciting activity in preclinical models and yet have had minimal activity clinically. These disappointments have led to reasonable scepticism about the true value of both syngeneic and xenograft rodent tumour models in accurately identifying agents that will have important clinical utility. Whereas the Development of newer techniques, including transgenic mouse models of Cancer, offers the potential to develop more predictive models, the role of such mice in Cancer Drug Development is not yet validated. To advance in our understanding of predictive model systems it may be wise to analyse both the successes and the failures of conventional models in order to understand some of their limitations and perhaps to avoid making the same mistakes in the future. Here we review the value and limitations of xenograft models, and the role of integrating preclinical pharmacology in developing new treatments for solid tumours of childhood.
Neena Lal - One of the best experts on this subject based on the ideXlab platform.
-
PET in anti-Cancer Drug Development and therapy.
Recent patents on anti-cancer drug discovery, 2007Co-Authors: Rakesh Kumar, Neena LalAbstract:Anti-Cancer Drug Development is a major area of research. Monitoring of response to newer anti-Cancer Drugs has undergone an evolution from structural imaging modalities to targeting functional metabolic activity at cellular level to better define responsive and non-responsive Cancerous tissue. This review article highlights the contribution of Positron Emission Tomography (PET) in this field. PET holds a promising role in the future by providing us information pertaining to the Drugs effectiveness early in the course of therapy, so that side effects and expenses can be reduced substantially. PET has been used to measure changes in Drug induced metabolism, cellular proliferation and tissue perfusion. Also changes induced by immuno-modulating Drugs such as apoptosis, telomere activity, growth factor levels and many more can be studied using specific radiolabelled PET tracers whereas conventional imaging modalities which detect changes in tumor size and residual tissue histopathology may not prove useful in such scenario. In future, most PET scanners will be replaced by Hybrid PET-CT scanners, which provide functional and structural information in the same setting. In addition, PET-CT improves characterization of equivocal lesions and decreases interobserver variability. The most important recent patents concerning role of PET in Drug Development have been presented.
